UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number 001-43544
Zoar
Limited
(Translation
of registrant’s name into English)
1504,
15th Floor, Peninsula Square
18
Sung On Street, Hung Hom,
Kowloon,
Hong Kong
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Completion
of Merger and Commencement of Trading
On
November 17, 2026, Zoar Limited (the “Company”) consummated the previously announced business combination
pursuant to the merger and share exchange agreement, dated as June 21, 2025, as amended, involving the Company, Impact
Biomedical Inc., Zoar Labs Limited, Dr Ashleys Nevada Sub, Inc. and Kanas Visvanats (the “Business
Combination”).
In
connection with the completion of the Business Combination, the Company’s ordinary shares are expected to commence trading
on the NYSE American under the ticker symbol “ZOAR” on November 18, 2026.
On
November 18, the Company issued a press release announcing the completion of the Business Combination and the commencement of
trading, a copy of which is furnished as Exhibit 99.1 hereto.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| Date:
November 18, 2026 |
Zoar
Limited |
| |
|
|
| |
By: |
/s/
Kanans Visvanats |
| |
|
Kanans Visvanats |
| |
|
Chief
Executive Officer |
EXHIBIT
INDEX
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press
release, dated November 18, 2026. |
Exhibit
99.1

Zoar
Limited Completes Business Combination with Impact Biomedical Inc.
Zoar
Limited ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “ZOAR” on November 18,
2026.
The
Business Combination was approved by Impact Biomedical Inc.’s stockholders at a special meeting held on November 13, 2026.
Zoar
Labs, Zoar’s operating subsidiary, reported revenue of $651.7 million and net income of $77.7 million for the fiscal year ended
March 31, 2026.
Hong
Kong, November 18, 2026 — Zoar Limited (NYSE American: ZOAR) (“Zoar” or the “Company”), a global pharmaceutical
company focused on the development and manufacturing of complex active pharmaceutical ingredients (“APIs”) and intermediates,
today announced that it has completed its business combination involving the Company, Impact Biomedical Inc. (“Impact”),
Dr Ashleys Nevada Sub Inc. and Zoar Labs Limited (“Zoar Labs”) (the “Business Combination”). Zoar’s ordinary
shares are expected to begin trading on NYSE American under the ticker symbol “ZOAR” on November 18, 2026. In connection
with the completed Business Combination, each share of Impact common stock, which traded on the NYSE American under the ticker symbol
“IBO,” was converted into the right to receive one Zoar ordinary share.
“Completing
this business combination and listing on NYSE American is an important milestone for Zoar and for the customers and partners who have
supported us since our founding in 2012,” said Dr. Kanans Visvanats, Founder, Chairman, and Chief Executive Officer of Zoar. “Over
that time, we have grown into a supplier of APIs and intermediates to customers in more than 35 countries. We believe that access to
the U.S. capital markets will give us greater visibility with customers and investors, as well as additional flexibility to pursue our
growth strategy, including expanding our product offering in orphan drug APIs. I would like to thank the Impact team for their partnership
in bringing this transaction to completion, and we look forward to engaging with our new shareholders as a public company.”
Zoar
develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates in collaboration with selected contract
manufacturing organizations, and provides contract development and manufacturing (“CDMO”) services for complex APIs and intermediates
in specialized therapeutic areas. Its products span six therapeutic categories (anti-cancer, anti-coagulants, anti-malarial, anti-viral,
bronchodilators, and anti-respiratory) and are sold directly and through a network of approximately 100 distributors and pharmaceutical
partners across Europe, Africa, the Middle East, India, Asia, and Central and South America.
For
the fiscal year ended March 31, 2026, Zoar Labs, a wholly owned subsidiary of the Company, reported revenue of $651.7 million compared
to $556.4 million in the prior fiscal year, an increase of approximately 17.1%. Net income for the fiscal year ended March 31, 2026 was
$77.7 million compared to $62.7 million in the prior fiscal year, an increase of approximately 23.9%.
The
Business Combination was completed pursuant to the Merger and Share Exchange Agreement dated June 21, 2025, as amended. Under its terms,
a wholly owned subsidiary of Zoar merged with and into Impact, with Impact surviving as a wholly owned subsidiary of Zoar and being renamed
Zoar USA Inc., and Zoar acquired all of the issued and outstanding shares of Zoar Labs from its sole shareholder, Dr. Visvanats (the
“Zoar Shareholder”), in exchange for Zoar ordinary shares. Following the completion of the Business Combination, Zoar has
approximately 180.0 million ordinary shares outstanding, of which Zoar Shareholder held approximately 93.32%, and former Impact stockholders
held approximately 4.80%.

Zoar
is led by Dr. Kanans Visvanats, Chairman and Chief Executive Officer; Adrian Anthony Simon Markland, Chief Operating Officer; and Sameer
Ramesh Talim, Head of Sales and Marketing. The Company’s Board of Directors consists of eight members: Dr. Visvanats (Chairman),
Donald Kalkofen, Michael Zajas, Evan Lim, Neha Kumari, Maduabuchi Nelson Okey, Bang-Ning (Simon) Liu, and David A. Sanders.
Robinson
& Cole LLP served as U.S. legal counsel, Harney Westwood & Riegels served as Cayman Islands legal counsel, Wong Poon Chan Law
& Co. served as Hong Kong legal counsel, Marcum Asia CPAs LLP served as auditor, and BMI Capital International LLC served as advisor
to Zoar. Sichenzia Ross Ference Carmel LLP served as legal counsel and Grassi & Co., CPAs, P.C. served as auditor to Impact.
About
Zoar Limited
Zoar
Limited is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients and provides
contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. Zoar Limited currently offers
more than 35 pharmaceutical products to customers in over 35 countries.
Forward-Looking
Statements
This
press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other
than statements of historical fact are forward-looking statements. These statements may be identified by words such as “may,”
“could,” “will,” “should,” “would,” “expect,” “plan,” “intend,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,”
or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements in this press release
include, but are not limited to, statements regarding the expected commencement of trading of Zoar Limited’s ordinary shares on
the NYSE American; the anticipated benefits of the business combination; Zoar’s plans and strategies for growth, including any
plans to expand its product offering to include orphan drugs; and the expected benefits of access to the U.S. capital markets.
These
forward-looking statements are based on assumptions and on the current expectations of Zoar’s management and are not predictions
of actual performance. You should not place undue reliance on these statements because they are subject to risks, uncertainties, and
other factors, many of which are beyond Zoar’s control, that could cause actual events or results to differ materially from those
expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, risks relating to the completion
and integration of the business combination and the realization of its anticipated benefits; Zoar’s ability to execute its business
and growth strategies; the development, regulatory status, manufacture, quality, and commercialization of pharmaceutical products; Zoar’s
reliance on contract manufacturing organizations and other third parties; customer demand, competition, and market conditions; supply-chain
and operational disruptions; and the other risks described in Zoar’s filings with the U.S. Securities and Exchange Commission (the
“SEC”).
These
risks, uncertainties and other factors are, in some cases, beyond the Company’s control and could materially affect results. If
one or more of these risks, uncertainties or other factors become applicable, or if these underlying assumptions prove to be incorrect,
actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. Forward-looking statements contained in this announcement are made as of this date, and
the Company undertakes no duty to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware, except as required under applicable law.
Investor
Relations Contact
Gateway
Group, Inc.
(949)
574-3860
ZOAR@gateway-grp.com